outstand start core revenu growth
maintain buy rate maintain tp
estim tp base forward multipl
ep give upsid potenti
also estim top line
revenu growth
estim base follow factor strong growth
revenu life scienc diagnost busi strong
growth revenu high-growth market china india
lead way increas free cash flow improv
danah deliv strong result increas
revenu compar previou
year quarter
segment revenu life scienc diagnost busi
strong growth total revenu life scienc
segment increas quarter compar
total revenu diagnost segment
increas compar
total revenu dental segment increas
compar total
revenu environment appli solut quarter
increas compar
geograph high-growth market revenu grew
china india lead way develop market saw
mid-single-digit revenu growth europ low single-digit
growth north america
oper profit quarter compar
net earn increas
compar dilut
ep quarter increas compar
non-gaap dilut ep quarter
increas compar
compani name corporationtickerdhrstock ratingbuyunchangedindustri viewoverweightpositivepric may week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth corp may
incom statement
 guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
march enter facil
provid liquid support expans danah
 euro-denomin commerci paper program
gener corpor purpos use proce
issuanc dollar euro-denomin commerci
paper fund portion purchas price
acquisit april
oper cash flow continu oper increas
quarter compar
march held
billion cash cash equival
guidanc expect adjust ep
rang assum core growth gaap
ep expect rang
expect adjust ep
ep rang
current price-to-earnings multipl average
price-to-earnings price-to-earnings
increas sinc past year
stock price volatil
increas last year assum price-to-earnings
ytd stock perform compar
 roa ttm roe ttm
gener free cash flow result
growth y/i free cash flow net incom
convers ratio
deliv strong quarterli result shown
strong growth life scienc diagnost segment
maintain buy rate maintain tp
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short n/a short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date apr ex-dividend date last split factor new per last split date jul inform danah corp may
incom statement
 guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
incom statement item total gross research develop sell gener administr sg oper oper profit interest incom special charges- interest incom minor incom incom net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli corp may
 market account receivable- total prepaid current assets- total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer current liabilities- total current long-term defer incom taxes- non-curr minor interest total non-curr total prefer stock equity- common stock addit paid-in retain treasuri stock- total total total liabil stock actual annual actual quarterli balanc sheet item danah corp may
oper cash flow continu oper increas compar
increas due higher earn lower cash use fund account receiv inventori
net cash use invest activ continu oper compar
cash use
financ activ continu oper use cash compar cash
use decreas cash use financ activ due lower net repay
commerci paper borrow compani accumul cash rather repay commerci
paper prepar acquisit close april
 defer incom taxes- oper increas decreas increas decreas current assets- decreas increas decreas increas current decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant purchas properti plant net invest financ activitiesissu issuanc capit repurchas capit stock- payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end danah corp may
danah deliv strong result increas revenu
compar previou year quarter non-gaap earn per
share increas quarter
life scienc diagnost busi strong growth revenu
life scienc busi increas compar
previou year period revenu diagnost busi increas
compar previou year period
result
increas revenu
compar previou
year quarter
cog increas compar
increas due impact higher y/i sale volum includ sale
recent acquir busi partli off-set increment y/i cost save
associ restructur continu product improv
action taken
increas bp
compar
gross profit compar gross profit
margin increas bp compar
increas gross profit margin due favor impact higher
y/i sale volum increas leverag certain manufactur cost
well impact increment y/i cost save associ
restructur activ continu product improv action taken
gross profit margin also posit impact weak
 dollar major currenc
sg expens increas compar
sg revenu decreas bp
compar y/i decreas sg expens
sale driven benefit increas leverag compani gener
administr cost base result higher sale volum
partial off-set continu invest sale market growth
 expens increas compar
 revenu flat
compar previou year quarter y/i increas spend
compani new product develop initi correspond increas
oper profit quarter compar
oper margin quarter compar
interest expens lower due
lower outstand commerci paper borrow
effect tax rate continu oper
compar effect tax rate slightli lower
 feder statutori rate due impact dhr earn
outsid gener tax rate lower feder
net earn increas compar
comprehens incom increas compar
due higher net earn three-month period partial
off-set decreas gain foreign currenc translat adjust
compar gain realiz foreign currenc translat
gain compar translat gain
dilut ep quarter increas compar
non-gaap dilut ep quarter increas
compar
declar regular quarterli dividend per share payabl
april holder record march free cash flow
increas compar
oper cash flow continu oper increas
quarter compar increas
primarili due higher earn lower cash use fund account
receiv inventori account payabl period compar
march held billion cash cash equival
march enter facil provid
liquid support expans danah euro-denomin
commerci paper program gener corpor purpos use
proce issuanc dollar euro-denomin commerci
paper fund portion purchas price acquisit april
continu
oper
compar
danah report segment consist life scienc diagnost dental
total revenu
increas
compar
total revenu life scienc segment increas
quarter compar non-gaap revenu growth
compar previou year quarter
oper profit quarter increas compar
oper profit margin increas bp
compar
core sale
busi broad rang
grew y/i basi
due
strong sale growth
primarili china
increas oper profit due
increment y/i cost save associ restructur action
continu product improv initi taken
impact weaker dollar
net increment y/i cost associ variou new product
develop sale market growth invest
core sale busi broad rang mass spectromet grew
y/i basi due strong sale growth high-growth market
primarili china western europ
core sale microscopi product grew primarili china
western europ across major end-market demand busi
flow cytometri particl count product line strong across major
geographi compar
core sale filtrat separ purif technolog increas
compar increas due continu growth
biopharmaceut microelectron end-market demand
filtrat separ purif technolog busi increas asia
particularli china partial off-set declin middl east
acquisit april provid addit sale earn growth
opportun segment expand segment product line
divers includ new product servic offer area genom
consum potenti futur acquisit complementari
total revenu
increas
compar
core sale
busi grew y/i
due new
product
advanc stain
total revenu diagnost segment increas
compar non-gaap revenu increas
compar previou year quarter
oper profit margin increas bp compar
oper profit compar
increas oper profit due
increment y/i cost save associ restructur action
continu product improv initi taken
impact weaker dollar net increment y/i cost
associ variou new product develop sale servic
core sale molecular diagnost busi contribut
significantli overal segment core growth strong perform
across major geographi product line consid strong growth
infecti diseas product line north america strong growth
infecti diseas product line driven part sever flu season
experienc quarter well test menu expans
core sale segment clinic lab busi increas y/i basi
demand high-growth market off-set modest declin
develop market increas demand immunoassay product line
drove major growth
core sale acut care diagnost busi increas y/i
due continu strong sale blood ga immunoassay analyz
consum geograph strong demand high-growth market
particularli china drove major growth sale y/i basi
acut care diagnost busi
core sale patholog diagnost busi grew y/i due
new product advanc stain core histolog product
line sale also increas across major geographi
total revenu dental segment increas
compar non-gaap revenu decreas
compar previou year quarter
oper profit quarter compar
oper margin fell bp quarter compar
segment increas
compar
declin oper incom due
lower sale dental equip tradit dental consum
increment y/i cost associ sale market growth
total revenu
solut increas
compar
increas spend product initi
net increment y/i cost save associ continu product
initi taken
impact weaker dollar
geograph strong y/i core revenu growth china high-
growth market off-set lower demand north
america western europ
core revenu growth specialti consum busi consist
implant system orthodont product led high-growth market
north america
lower core sale dental equip tradit dental consum
product line north america off-set y/i growth
specialti consum categori reflect compani
effort reduc amount inventori held sever distribut partner
well realign distributor manufactur dental
total revenu environment appli solut quarter increas
compar non-gaap revenu
increas compar previou year quarter
busi chemic
product line
driven higher
demand mine
power commerci
institut end-
lower demand
oil ga chemic
oper profit margin decreas bp compar
oper profit compar
oper profit margin favor impact due higher core
sale volum impact weaker dollar also
affect net impact increment y/i cost associ variou new
product develop sale market growth invest oper
profit margin unfavor impact due increment net dilut effect
acquir busi
core sale segment water qualiti busi grew mid-singl digit
rate compar y/i core sale analyt
instrument product line increas higher demand
industri municip end-market primarili north america china latin
america partial off-set lower demand environment end-market
core revenu growth busi chemic treatment solut product
line driven higher demand mine power commerci
institut end-market partial off-set lower demand oil
ga chemic end-market geograph y/i core revenu growth
product line driven increas demand high-growth market
north america
core sale busi ultraviolet water disinfect product line increas
compar due higher demand particular strength
municip end-market china
core sale segment product identif busi grew mid-
singl digit rate compar continu strong y/i
demand mark code equip relat consum
major geographi led western europ high-growth market north
america drove major core revenu growth
continu demand color solut product servic led north
america western europ also contribut core revenu growth
y/i core sale increas modestli packag product led
demand north america western europ partial off-set declin high-
guidanc conclus
expect adjust ep rang
assum core growth ep expect
rang
expect adjust ep ep
rang
deliv strong result first quarter revenu increas
compar previou year quarter adjust ep
increas compar
life scienc diagnost busi strong growth life
scienc busi revenu increas diagnost busi revenu
increas compar previou year quarter
geograph high-growth market revenu grew china india
lead way develop market saw mid-single-digit revenu
growth europ low single-digit growth north america
gross profit margin increas bp compar
effect tax rate continu oper
compar net earn increas
compar
ytd stock perform compar roa
ttm roe ttm gener
free cash flow result growth y/i free cash flow net
incom convers ratio
adjust ep
ep
rang
revenu increas
diagnost
increas
compar
previou year
non- reconcili
non- reconcili
non- reconcili
incom statement
 guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin ttm basi gross margin end decemb
sg ttm basi percentag revenu respect
revenu growth ttm basi oper incom ttm basi ep growth
ttm basi
free cash flow/sal ttm basi free cash flow/net incom
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth corp may
mrqgross mrqcog mrqoper mrqsg mrqnet mrqr sale danah corp may
inv flow sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqreturn mrqreturn mrqfinanci leverag danah corp may
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer dividends- annual itemsquarterli item danah corp may
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant equipment- purchas sale business- purchas investment- sale issuanc repurchas stock- net issuanc prefer stock- net issuanc net chang capit free corp may
current price-to-earnings multipl average price-to-earnings price-to-earnings
increas sinc past year stock price
volatil increas last year assum price-to-earnings
incom statement
 guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold direct holder form daniel thoma patrick donald jame alan angela institut holdersholdershar report outvaluepric row associ vanguard group inc massachusett servic fmr wellington manag compani morgan america parnassu invest top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard parnassu equiti price row capit appreci spdr etf vanguard institut fund-institut mf seri trust i-mf valu price row chip growth fund ishar fidel competit
develop acquir integr dna corpor integr dna announc enter definit agreement acquir privately-held provid high-valu consum genom applic molecular biolog qpcr next gener sequenc synthet biolog gene edit molecular diagnost oper stand-alone oper compani brand within life scienc platform wsj approach ge deal life scienc unit express interest deal gener electr life scienc busi ge engag isnot interest deal deal could gave valu structur propos transact known activ discuss underway grow leverag life scienc improv long-term outlooklif scienc diagnost led way unusu flu season boost cepheid bioproduct continu grow march corp may
incom statement
 guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
perform
compar
gross margin
higher compar
roa roi roe ttm
basi stood
respect
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit corp may
consensu view analyst trend stock
rate expect
lower
growth rate
dhr forward price-to-earnings
higher
dhr avgfive-year growth forecast usdgrowth high day day day estim comparisondhrindustri avg avgprice/earn yield corp may
consensu view analyst trend stock
averag earn estim
current quarter next
quarter
sale growth estim current
quarter next quarter
deliv strong result
top line growth
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr danah corp may
incom statement
 guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
chart show volatil stock price trade around
stock given total return last month
stock seen steadi rise price past one year reach high
stock given return past one year
stock increas consist sinc given return last year
crispidea price target maintain base price-to-earnings multipl ep
deliv strong quarterli result shown strong growth life scienc diagnost
segment estim strong perform given buy rate stock
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
